MediWound Announces Collaboration with Mölnlycke on EscharEx Phase III Study

MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx in venous leg ulcers (VLUs). Mölnlycke will provide Mepilex Up, its most recent line extension to its global market leading brand, along with Exufiber and Exufiber Ag dressings to be used during the wound healing phase of the study.

“We've tailored our strategy for the upcoming Phase III VLU study in accordance with the U.S. Food and Drug Administration (FDA) recommendations to reduce variability. Restricting the number of wound dressing options is critical to successfully achieve the trial's endpoints. Mölnlycke’s Mepilex dressings are the leading brand used worldwide in the largest category of wound dressings: foams,” stated Dr. Robert Snyder, Chief Medical Officer, of MediWound. “Effective wound fluid management is crucial for the optimal healing of VLUs, which is why we are pleased to provide our study participants Mepilex Up, the most recent extension to the Mepilex line and specifically designed for this use.”

EscharEx is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During the wound healing phase of the study, Mölnlycke’s wound dressings will be used as standard of care in all study arms, until the wounds reach complete healing.

“Mepilex has been a market-leading brand for almost 20 years. With our recent launch of Mepilex Up, we now can offer a unique dressing for use underneath compression systems. Given that MediWound’s Phase III study is focusing on venous leg ulcers, this is the perfect setting in which to showcase this advanced dressing as the standard of care,” stated Kacee Huguely, VP of US Wound Care Marketing of Mölnlycke. “We look forward to participating in this critical study and to supplying patients with our best-in-class dressings to help ensure optimal outcomes.”